News

New Genomic Framework Brings Precision Medicine to CMML Treatment

Research Advances /

A new international study introduces a precision medicine framework for Chronic Myelomonocytic Leukemia (CMML), a rare blood cancer that has lacked personalized treatment strategies. By combining genomic data with clinical information, the model improves diagnosis, survival prediction, and decisions about when to perform bone marrow transplants. Researchers identified nine genomic subtypes covering about 69% of […]

New Genomic Framework Brings Precision Medicine to CMML Treatment Read More »

Liquid Biopsies Show Promise in Guiding Bladder Cancer Treatment

Technology Innovation /

Liquid biopsies are emerging as valuable tools in bladder cancer care.  By analyzing circulating tumor DNA (ctDNA) in blood and urinary tumor DNA (utDNA), doctors can better assess risk and monitor disease compared to traditional methods alone. Tumor-informed ctDNA tests, such as Signatera, are increasingly used to detect minimal residual disease and guide treatment decisions.

Liquid Biopsies Show Promise in Guiding Bladder Cancer Treatment Read More »

New Drug UNC569 Shows Promise Against Resistant Pancreatic Cancer

Treatment /

Researchers have identified a new small-molecule drug, UNC569, as a promising therapy for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest and most treatment-resistant cancers. UNC569 targets the MerTK receptor, which helps cancer cells survive and spread, triggering cancer cell death and overcoming drug resistance. The drug works through a “two-pronged” mechanism. First, it induces

New Drug UNC569 Shows Promise Against Resistant Pancreatic Cancer Read More »

PHIP Protein Identified as New Target in Hard-to-Treat Cancers

Research Advances /

Researchers have discovered a new therapeutic target, PHIP, for cancers driven by SWI/SNF mutations, including aggressive pediatric rhabdoid tumors. These cancers are hard to treat because the mutations remove tumor-suppressor proteins, leaving no direct target. The team found that PHIP is essential for cancer cell survival when SWI/SNF is lost. Normally, SWI/SNF activates genes while

PHIP Protein Identified as New Target in Hard-to-Treat Cancers Read More »

Reduced-Dose TIL Therapy Improves Safety for Elderly Melanoma Patients

Treatment /

A study shows that a reduced-dose conditioning regimen can make tumor-infiltrating lymphocyte (TIL) therapy safer and more tolerable for older or frail patients with metastatic melanoma. Researchers cut the cyclophosphamide dose in half while keeping fludarabine at the standard level. Seventeen high-risk patients, aged 66–78, were treated, many with brain metastases or other health issues.

Reduced-Dose TIL Therapy Improves Safety for Elderly Melanoma Patients Read More »

Nuvalent Seeks FDA Approval for ALK-Targeted Lung Cancer Drug Neladalkib

Treatment /

Nuvalent has submitted a New Drug Application (NDA) to the FDA for neladalkib (NVL-655), an ALK-targeted therapy for advanced ALK-positive non–small cell lung cancer (NSCLC) in patients previously treated with tyrosine kinase inhibitors (TKIs). The submission is based on the Phase 1/2 ALKOVE-1 trial, which included patients treated with lorlatinib or chemotherapy. The trial showed

Nuvalent Seeks FDA Approval for ALK-Targeted Lung Cancer Drug Neladalkib Read More »

Scientists Reveal Hidden “Spring-Loaded” Switch That Activates Cancer-Fighting T Cells

Research Advances /

Researchers have discovered how T cells switch from a resting state to an active attack, revealing a hidden motion in T cell receptors that helps explain how the immune system detects cancer. Using advanced cryo-electron microscopy, the team found that T cell receptors remain tightly closed and inactive until they encounter an antigen. At that

Scientists Reveal Hidden “Spring-Loaded” Switch That Activates Cancer-Fighting T Cells Read More »

Precision Medicine Advances Transform Colorectal Cancer Treatment in 2026

Precision Medicine /

Colorectal cancer research in early 2026 is increasingly focused on precision medicine, using biomarkers to guide treatment decisions for different patient groups. One major approach is using circulating tumor DNA (ctDNA) to decide who needs chemotherapy after surgery. Patients with no detectable ctDNA may safely avoid chemotherapy, while those with positive ctDNA—indicating a higher risk

Precision Medicine Advances Transform Colorectal Cancer Treatment in 2026 Read More »

MethylScan Blood Test Detects Multiple Diseases for Under $20

Diagnostics /

Researchers have developed MethylScan, a low-cost blood test that can detect multiple cancers, liver diseases, and organ abnormalities by analyzing DNA fragments in the bloodstream. Instead of searching for rare mutations, it examines DNA methylation, chemical markers that reflect tissue health. The test filters out background DNA from healthy blood cells, improving accuracy while reducing

MethylScan Blood Test Detects Multiple Diseases for Under $20 Read More »

Nanotherapy Breakthrough Doubles Survival in Preclinical Glioblastoma Study

Treatment /

Researchers have developed a new experimental nanotherapy that shows strong potential against glioblastoma, one of the most aggressive brain cancers. The treatment uses tiny lipid-based particles called liposomes that can cross the blood-brain barrier. These particles deliver two drugs—everolimus (or rapamycin) and vinorelbine—directly into tumor cells at the same time. In preclinical studies, combining this

Nanotherapy Breakthrough Doubles Survival in Preclinical Glioblastoma Study Read More »